Recce Pharmaceuticals Announces Safety Committee Approves Ne

Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Announces Safety Committee Approves Next Dose of RECCE® 327 at 3,000mg in Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , New Zealand , Sydney , New South Wales , Australia , Andrew Geddescity , James Graham , Guillame Van Renterghemlifesci , Media United States Jordyn Temperatolifesci Communications , Recce Pharmaceuticals Ltd , Safety Committee , Recce Pharmaceuticals , Recce Pharmaceuticals Ltdrecce Ltd , Corporate Contactjames Grahamrecce Pharmaceuticals Ltd , Independent Safety Committee , Pharmaceuticals Ltd , Chief Executive Officer , Australia New Zealand Clinical Trial Registry , New Class , Synthetic Anti Infectives , Infectious Disease Product , Generating Antibiotic Initiatives Now , Fast Track Designation , Pew Charitable Trusts Global New Antibiotics , Development Pipeline , Contactjames Grahamrecce Pharmaceuticals , Investor Relations , Jordyn Temperatolifesci ,